Accessibility navigation

Diagnosis and management of posterior cortical atrophy

Yong, K. X. X. ORCID:, Graff-Radford, J., Ahmed, S., Chapleau, M., Ossenkoppele, R., Putcha, D., Rabinovici, G. D., Suarez-Gonzalez, A., Schott, J. M., Crutch, S. and Harding, E. (2023) Diagnosis and management of posterior cortical atrophy. Current Treatment Options in Neurology, 25 (2). pp. 23-43. ISSN 1534-3138

Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.

Text (Correction) - Supplemental Material
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1007/s11940-022-00745-0


Purpose of review: The study aims to provide a summary of recent developments for diagnosing and managing posterior cortical atrophy (PCA). We present current efforts to improve PCA characterisation and recommendations regarding use of clinical, neuropsychological and biomarker methods in PCA diagnosis and management and highlight current knowledge gaps. Recent findings: Recent multi-centre consensus recommendations provide PCA criteria with implications for different management strategies (e.g. targeting clinical features and/or disease). Studies emphasise the preponderance of primary or co-existing Alzheimer’s disease (AD) pathology underpinning PCA. Evidence of approaches to manage PCA symptoms is largely derived from small studies. Summary: PCA diagnosis is frequently delayed, and people are likely to receive misdiagnoses of ocular or psychological conditions. Current treatment of PCA is symptomatic — pharmacological and non-pharmacological — and the use of most treatment options is based on small studies or expert opinion. Recommendations for non-pharmacological approaches include interdisciplinary management tailored to the PCA clinical profile — visual-spatial — rather than memory-led, predominantly young onset — and psychosocial implications. Whilst emerging disease-modifying treatments have not been tested in PCA, an accurate and timely diagnosis of PCA and determining underlying pathology is of increasing importance in the advent of disease-modifying therapies for AD and other albeit rare causes of PCA.

Item Type:Article
Divisions:Life Sciences > School of Psychology and Clinical Language Sciences > Department of Psychology
ID Code:110707
Uncontrolled Keywords:Dementia (J Pillai, Section Editor), Topical Collection on Dementia, Posterior cortical atrophy, Alzheimer’s disease, Visual variant Alzheimer’s disease, Visual processing, Atypical Alzheimer’s disease, Treatment
Additional Information:A Correction to this article was published on 21/03/23 and is available here:
Publisher:Springer US


Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation